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ABSTRACT 
 
 
Introduction: 
 
Long-term mortality after lower extremity amputation is not well reported in low- and middle- 
income countries. The primary aim of this study was to report 30-day and one-year mortality 
after lower extremity amputation in South Africa. The secondary objective was to report risk 
factors for one-year mortality. 
 
 
Methods: 
 
This was a retrospective cohort study of patients undergoing lower extremity amputations at 
New Somerset Hospital from October 1, 2015, to October 31, 2016. A medical record review 
was undertaken to identify co-morbidities, operation details, and perioperative mortality rate. 
Outcome status was defined as alive, dead, or lost to follow-up. Outcomes at 30 days and one 
year were reported. 
 
 
Results: 
 
There were 152 patients; 90 (59%) males and the median age (interquartile range, IQR) was 
60 (54-67) years. At 30 days, 102 patients were traced and 12 (12%) were dead. At one year, 
86 (57%) were traced and 37 (43%) were dead. 
 
Conclusion 
 
At this South African hospital, 43% of patients undergoing lower extremity amputations were 
dead after one year. In resource-constrained settings, mortality data are necessary when 
considering resource allocation for lower extremity amputations and essential surgical care 
packages.
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LITERATURE REVIEW 
 
1. Background 
 
Amputation is the surgical removal of all or part of a limb or extremity. The word amputation 
is originally derived from the Latin amputare, which means "to cut away". Amputation is an 
old surgical procedure and was described as early as 1700 BC. Furthermore, Rig-Veda 
recorded the first amputation and prosthesis done for the leg of Queen Vishpla, where an iron 
leg was fitted after wound healing to allow mobility and returning back to the battlefield in 
the second millennium BC.1 However, amputation was more commonly performed for 
criminal punishment and not routinely performed for medical reasons until the 17th century 
after which, the English word "amputation" became an accepted medical term. 
 
2. Incidence 
 
Lower extremity amputation (LEA) is much more common than upper extremity amputation. 
LEA is a common general, vascular, or orthopaedic surgical procedure. It is challenging to 
determine the prevalence as many countries do not record amputations. There are variations in 
LEA incidence worldwide. LEA is due to a variety of factors but diabetes mellitus (DM) and 
its associated complications are major contributors in patients requiring LEA.2 The 
introduction of specialized diabetic foot care clinics2 and vascular interventions3,4 can help 
delay LEA. However, often LEA is still needed despite vascular intervention.5,6 Furthermore, 
the rate of LEA remains unchanged in the past two decades. This is partly due to an ageing 
population and therefore rise in atherosclerosis, DM, and peripheral vascular disease 
(PVD).7,8,9 In high income countries (HICs) such as the United States (US), approximately 
185,000 persons undergo LEA annually.10 However, in South Africa there are no publications 
of lower limb amputations epidemiology.11 
 
3. Level of Amputation 
 
Minor LEAs are ones below the ankle such as toe removal (known as Ray’s amputation), and 
trans metatarsal amputation (TMA). LEAs above the ankle are considered major amputations 
and include supramalleolar amputation (SMA), below the knee amputation (BKA), and above 
the knee amputation (AKA). 
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The level of LEA depends on the level of arterial disease and/or the location of the soft tissue 
lesion or sepsis. The determination of the level of LEA is usually based on clinical examination 
to determine the degree of the disease, potential wound healing based on blood supply, extent 
of sepsis, and consideration of rehabilitation options.12,13 
 
In a study from Amsterdam, 90% of AKA and 80% BKA resulted in good wound healing 
based on clinical decisions without need for additional radiologic tests.14 While preservation 
of limb length is desirable, excision and removal of dead and infected tissue are more 
important. If the clinical assessment is not sufficient to determine the level of amputation, 
there are other tests such as skin perfusion pressure, transcutaneous oxygen measurements, 
and ankle and toe pressure tests. However, due to their low sensitivity for wound healing 
prediction, they must be used as an addition and cannot replace clinical assessment.14,15,16 
 
4. Emergency LEA 
 
Emergency amputation can be performed in one step or two steps (also known staged 
operation). In a one-step procedure, a formalized surgical amputation is performed. In a 
staged operation, the first step is a guillotine amputation for sepsis control and the second is 
the formalized surgical amputation which considers the future rehabilitation and patient 
mobility. In surgical practice, a guillotine amputation is an amputation performed in an urgent 
setting as a quick procedure without closure of the skin. Typical indications include infection 
control due to infected gangrene (wet or gas gangrene) and catastrophic trauma from a 
severely crushed limb. LEA can be performed electively if the patient is hemodynamically 
stable, systemically not septic, and the existing sepsis can be controlled with simple drainage 
of abscess or debridement of necrotic tissue combined with antibiotic cover. In patients with 
sepsis that cannot be controlled locally, an emergency LEA should be carried out without 
delay.17,18 
 
5. Indications for LEA 
 
In HICs, the main indications are vascular disease, DM, and peripheral arterial disease (PAD), 
trauma, and less commonly, cancer.10 Advanced DM and PAD can result in an unsalvageable 
limb (without an option of revascularization), severe infection after failed treatment, or 
patients with medical risk factors that contraindicate revascularization.19 
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DM is a significant risk factor for LEA. Poorly controlled blood sugar aggravates vascular 
damage, that results in organ blood flow reduction, and indirectly reduces the efficacy of the 
immunity by reducing the chemotactic mechanism and phagocytic function. In addition, DM 
results in peripheral neuropathy which affects motor and sensory function. The small joints of 
the foot are susceptible to deformity that increases the chance of trauma especially from tight 
shoes, as there is a sensory defect. The small injuries cannot be detected until they get 
infected. Furthermore, the infection is difficult to control because of impaired blood flow that 
impedes the normal defence mechanism, making dead tissue a good media for pathogen 
proliferation and spread to healthy tissue.20,21 
 
PAD affects the arterial supply to limbs, leading to narrowing or obstruction of the blood 
vessels and ischemia of the limb. Older age, hypertension, tobacco use, diabetes, 
hypercholesterolemia, and atherosclerosis are well-known risk factors for the development of 
PAD.22,23 Specifically, atherosclerosis is notable risk factor. It can lead to thromboembolic 
disease, affecting the blood supply and contributing to risk of LEA.  
 
Trauma is the second most common indication for LEA. LEA is performed when limb 
salvage cannot be done due to compartment syndrome, massive tissue destruction, or for 
uncontrolled bleeding. LEA can be performed for penetrating and blunt trauma including road 
traffic accidents, other severe accidents such as electric shock.24,25 
 
Bone and soft tissue cancers that cannot be managed with local resection, radiotherapy, or 
chemotherapy may require LEA.26 Other indications include, debilitating extremity paralysis 
and severe deformity (e.g. paraplegia) from infection or pressure-related complications. 27 
 
Historically, traumatic injuries were the leading cause of LEA in low- and middle- income 
countries (LMICs);28,29 however, as non-communicable diseases (NCDs) in LMICs are 
increasing and infectious diseases are still prevalent, these nations are facing a double burden 
of medical indications for LEA.30 
 
Amputation is indicated if revascularisation is considered inappropriate in bedridden patients, 
in a functionally useless limb, in patients with life threatening sepsis, extensive muscle 
necrosis and where it is technically impossible. Primary amputation is better in these 
cases.31,32 
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6. LEA Procedures  
 
Amputation procedures can be performed using different kinds of anaesthesia based on the 
level of amputation and general patient condition. The operation can be performed under local 
anaesthesia or nerve block for minor amputations such as Ray’s amputation, and regional, 
spinal, and general anaesthesia for higher levels. Amputations are composed of different steps 
starts with bleeding control by ligating the supplying artery and vein, muscle transaction, and 
bone cutting. The bone should be covered with skin and muscle flap created during the 
procedure. The choice of a procedure is based on the clinical examination. In select cases 
when the choice of operation cannot be made on clinical examination alone, duplex 
ultrasound, digit photoplethysomgraphy, and transcutaneous measurement of oxygen pressure 
can aid in determining the choice of operation.33,34 In some cases, revascularization or 
angioplasty is considered based on patient and disease condition, and when facilities, 
equipment and skilled vascular surgeons are available. 
 
7. Post-Operative Complications After LEA 
 
Surgical procedures can result in early or late (30-day, or later respectively) postoperative 
complications depending on the type of surgery and pre-existing patient risk factors. One 
early complication is the need for re-operation because of a non-healing wound stump due to 
impaired blood flow. LEA associated with sepsis, end-stage renal disease, systemic 
inflammatory response syndrome, a body mass index greater than 30, intraoperative surgical 
trainee participation, and smoking are usually factors that lead to additional amputation(s).35 
Furthermore, the more distal the amputation, the more likely the chance for higher amputation 
in the future.33,34 If local sepsis is not adequately controlled, this could lead to complications 
including, superficial infection, deep infection, bleeding stump, and/or wound breakdown. 
Sepsis may progress in severity from local infection and bacteremia to septic shock, resulting 
in multiple organ dysfunction syndromes (MODS) and death. In acute respiratory distress 
syndrome (ARDS) as a result of severe organ dysfunction, disseminated intravascular 
coagulation (DIC), or acute kidney injury (ALI), there is an increase in the mortality rate 
based on the severity of sepsis.22 Septic shock and thrombocytopenia are independent risk 
factors for in-hospital mortality following AKA.36,37 
 
Cardiac complications, sepsis, and pneumonia are the main causes of perioperative mortality 
following LEA for patients with PAD.38,39 Postoperative lung complications are a common 
 5 
cause of morbidity and mortality. Pneumonia and atelectasis account for most of these 
complications. Pneumonia is one of the most common causes of post LEA 30-day mortality. 
Pulmonary complications can be reduced by good postoperative pain control and 
physiotherapy.38,39 Other complications after LEA include surgical site infection, hematoma, 
deep venous thromboembolism, atelectasis, and pneumonia.40  
 
8. Post-Operative Mortality 
 
Post-operative mortality is usually reported as peri-operative mortality rate (POMR), 30-day 
(30DM), one-year (1YM), or five-year mortality (5YM). The (POMR) is defined as death in 
the operating theatre or prior to discharge. Early mortality is defined as death within 30 days 
and late mortality is death one-year or later after operation.41 
 
Long-term mortality after LEA is high in HICs. Large series studies from HICs report 30DM 
from 9- 30%,42,43 and a meta-analysis demonstrated a 48% 1YM.44 In the 1960s and 1970s, 
some sites reported early mortality as high as 40%,45,46,47 but more recent studies reported 
rates between 3-18%,33,17,48,49 with one systematic review reporting 22% early mortality.50 
1YM has been reported as 20-35% following BKA, and 40-50% after AKA.33,17,49,51 Mortality 
is higher in diabetic patients and those on regular dialysis.49 For those with vascular disease, 
nearly all were dead at five years.52 
 
Long-term mortality after surgical procedures is not easily measured in LMICs given the lack 
of systematic post-operative follow-up. POMR is known to be higher than in HICs especially 
after emergency procedures.53 In a systematic review from Nigeria, POMR was reported as 
11% although 30DM and 1YM were not captured.29 A systematic review of all LEA for DM 
in Africa reported a 14% POMR.54  
 
9. Risk Factors for Mortality after LEA 
 
Emergency versus Elective 
 
Emergency LEA is associated with higher mortality than electives LEA. A delay in 
performing an emergency LEA increases POMR by 2% for every day of delay.50 A guillotine 
amputation, which is often performed in an emergency setting compared with an elective 
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setting, is associated with increased 30-day postoperative mortality.17 The 30DM rate in a 
study from the US was 14% for guillotine amputation and 8% for one step amputation.17 
 
Level of amputation 
 
Mortality following minor lower limb amputation is 2-7%.55,56 However, a minor amputation 
is often followed by a subsequent major amputation, which is associated with increased 
mortality. The higher the level of amputation, the greater the mortality. For example, one 
meta-analysis reported the mortality rate for BKA was 7% compared with 13% for AKA.44 
The association between the higher level of amputation and the higher mortality rate may be 
related to the severity of the indication, rather than the operation itself.44 
 
Primary versus Secondary 
 
A primary amputation is when no prior intervention has been performed, while secondary 
amputation is an amputation following a failed operative attempt to salvage the limb. Limb 
revascularization and endovascular angioplasty reduces the rate of major LEA, but increases 
the rate of minor amputations. The 30DM is lower after revascularization compared with 
without revascularization.38,57 
 
Comorbidities associated with LEA 
 
Comorbidities such as DM, arteriosclerosis, coronary artery disease, cerebral vascular disease, 
and end-stage renal disease increases post-operative mortality after LEA.17,44,58  
 
Peripheral arterial disease and coronary arterial disease 
 
PAD is a common risk factor for amputation. This is because PAD leads to chronic limb 
ischemia, which can result in severe pain, gangrene, or sepsis, which are indications for 
amputation.59 PAD and coronary arterial disease (CAD) are strongly correlated.60 Amputation 
in a patient with cardiovascular disease is associated with increased peri- and post-operative 
morbidity and mortality,61 largely a result of cardiac complications.54 
 
Diabetes mellitus  
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DM contributes to the need for LEA. A study in Cape Town, South Africa found that majority 
of LEA performed were for patients with DM. People with DM were more likely to require 
multiple LEA and operations.62 Long-standing and poorly-controlled DM causes diabetic 
nephropathy and impaired kidney function, atherosclerosis, ischemic heart disease, and intra- 
and extra-cranial cerebrovascular disease; all of which are associated with higher morbidity 
and mortality. In diabetic patients, the risk of PAD and ischemic events is higher compared 
with non- diabetic patients.63 
 
In one study, there was no difference between AKA and BKA in both early and late 
postoperative mortality among diabetic patients.39 However, another study found significant 
differences between the two amputation levels. The 1YM was 43% for AKA and 25% for 
BKA, and the 5YM was 66% in BKA and 83% in AKA.64 
 
Diabetic patients who developed diabetic nephropathy with end stage renal disease (ESRD) 
are at risk of major post-LEA complications, especially if the indication of the amputation is 
sepsis.65 However, random blood sugar level has no effect on the outcomes of 30-day LEA.66 
 
Smoking 
 
Smoking diabetic patient usually undergoes more amputations compared with a non-smoking 
diabetic patient.61 The impact of smoking is exacerbated by the number of cigarettes and 
duration. Furthermore, smoking is associated with delayed wound healing.67 In relation to 
mortality after amputation, smoking leads to chronic obstructive pulmonary disease (COPD), 
PAD, and cardiovascular disease, which increases mortality.68 
 
Renal impairment 
 
Renal failure increases postoperative mortality by threefold in patients undergoing LEA.69 
 
Immunosuppression and malnutrition 
 
The use of steroids and immunosuppressive medication, and low albumin levels are 
recognized risk factors for delayed wound healing. They also increase the risk of surgical site 
infection, post-operative morbidity, prolonged hospital stay, and post-LEA mortality.58,69 
 
 8 
Trauma-related LEA 
 
Historically, traumatic injuries were the leading cause of LEA in LMIC.28,29 LEA as a result 
of isolated lower extremity injuries has a lower mortality rate than polytrauma. Often, 
mortality due to trauma is related to concomitant organ injuries including head injuries, torso, 
and pelvic injuries. The mortality rate after LEA is higher with blunt trauma compared with 
penetrating trauma. In blunt extremity injuries among civilians, mortality is 5-10%.24,25  
 
Age 
 
Age greater than 80 years old is a risk factor for increased LEA postoperative mortality. 43,69 
 
10. Decreasing Mortality after LEA 
 
Appropriate medical management may play a role in reducing the morbidity and mortality of 
LEA. The best results following LEA are achieved through a multidisciplinary approach. This 
involves physiotherapy for rehabilitation, and improved mobility with the use of walking aids 
or prosthesis. Pain management and reduction of postoperative risk of complications, such as 
pulmonary complications is important. In addition, the role of psychological treatment is 
crucial, as there is a risk of developing post amputation depression. Furthermore, social 
workers and occupational therapists are involved to support and help with potential physical 
disability resulting from losing one limb or more.  
 
A multidisciplinary approach helps reduce the 30DM post-LEA. Preoperative assessment, 
identification of medical risk factors and appropriately addressing them, and nutritional 
assessment should proceed any amputation to reduce postoperative morbidity and mortality.33  
 
Statins are recommended by vascular surgeons as part of the best medical treatment plan for 
patients with PAD. They are the drugs of choice to reduce high blood cholesterol, which is a 
risk factor for cerebrovascular disease. Statin use is associated with reducing all- cause 
mortality, cardio and cerebrovascular events, and the rate of revascularization. Statin 
treatment reduced mortality caused by coronary artery disease, cardiovascular disease, 
cerebrovascular disease.70 In terms of LEA, statin therapy reduces 90 day or more mortality 
but there is no association with early (30-day) mortality.71 
 
 9 
Appropriate medical management plays a role in reducing the morbidity and mortality burden 
of LEA. Among a cohort of elderly vulnerable patients with medical comorbidities who are at 
high risk of early postoperative mortality, a multidisciplinary approach reduced the 30DM 
post-LEA from 40-10%. The multidisciplinary approach included an experienced physician, 
comprehensive evaluation of risk factors, no delays in surgical care, and availability of post-
operative elderly care unit. 72 
 
11. LEA as an Essential Procedure 
 
As discussed, LEA is a crucial procedure. However, LMICs often have health systems with 
limited resources. In these countries, best buys, or interventions that can achieve the greatest 
health impact with available resources, need to be prioritized when choosing the basket of 
procedures to be included in essential regional and national surgical packages.73 
 
LEA is an expensive procedure and a large number of patients need it. There is a paucity of 
data on the cost of LEA in LMICs. In the UK, a prospective study looked at the cost of 
surgical intervention to salvage or amputate the limb, with the results demonstrating that 
primary amputation is £10,162, with additional potential costs of: reconstruction (£6,766), 
angioplasty (£6,611), and revascularization (£3,970). However, a notable cost of LEA is the 
prolonged hospital stay and rehabilitation.74 
 
However, several factors beyond direct cost are needed to set surgical priorities including 
quality-adjusted life years gained, indirect costs to the health system and patient, and post-
operative outcomes such as mortality. Ease of suffering and respect and dignity are also issues 
of concern when assessing the impact of an intervention.73,75 There is a need for data and 
research on these various factors to help determine if procedures are a “best buy.” 
 
12. Summary 
 
LEA is a common operation worldwide and associated with significant early and late post- 
operative mortality. Vascular disease caused by PAD and DM is the most common indication 
for LEA. Trauma is a more common indication in LMICs than in HICs.  Risk factors for 
mortality include higher level of amputation, PAD, DM, and other pre-existing comorbidities. 
However, long-term mortality after LEA is not well reported in LMICs. The primary aim of 
this study was to report 30-day and one-year mortality after LEA in South Africa. The 
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secondary objective was to report risk factors for one-year mortality. Mortality data are an 
important part of determining if a procedure is a best buy in LMICs.  
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2. Abstract 
 
Abstract 
 
 
Introduction 
Long-term mortality after lower extremity amputation is not well reported in low- and 
middle- income countries. The primary aim of this study was to report 30-day and one-year 
mortality after lower extremity amputation in South Africa. The secondary objective was to 
report risk factors for one-year mortality. 
 
Methods 
This was a retrospective cohort study of patients undergoing lower extremity amputations at 
New Somerset Hospital from October 1, 2015, to October 31, 2016. A medical record review 
was undertaken to identify co-morbidities, operation details, and perioperative mortality rate. 
Outcome status was defined as alive, dead, or lost to follow-up. Outcomes at 30 days and 
one year were reported. 
 
Results 
There were 152 patients; 90 (59%) males and the median age (interquartile range, IQR) 
was 60 (54-67) years. At 30 days, 102 patients were traced and 12 (12%) were dead. At one 
year, 86 (57%) were traced and 37 (43%) were dead. 
 
Conclusion 
At this South African hospital, 43% of patients undergoing lower extremity amputations were 
dead after one year. In resource-constrained settings, mortality data are necessary when 
considering resource allocation for lower extremity amputations and essential surgical care 
packages. 
 
Key words: surgery, amputation, post-operative mortality, health systems 
strengthening
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3. Text of Article 
 
 
Introduction 
 
Surgical care can prevent disability and save millions of lives per year.1 Surgical care 
is known to be cost-effective and in 2015, the World Health Assembly declared that 
essential and emergency surgical procedures should be part of universal health care.2 
The majority of the surgical burden is in low- and middle- income countries (LMICs) 
which have health systems with limited resources.1 In these countries, best buys, or 
interventions that can achieve the greatest help impact with the available resources, 
need to be considered when choosing what procedures are included in essential 
national and regional surgical packages.3 Procedures with high mortality rates may 
not be ideal to include. Knowing the long-term survival after specific surgical 
procedures in each setting provides important information for policymakers as they 
determine essential surgical packages. 
 
Mortality after surgical procedures is not easily measured in LMICs given the lack of 
systematic post-operative follow-up. Peri-operative mortality (POMR) or in-hospital 
mortality is known to be higher in LMICs than in high-income countries (HICs), 
especially after emergency procedures.4  
 
In HICs, lower extremity amputation (LEA) is a common general surgical procedure 
for end-stage complications of the peripheral vascular disease (PVD) and diabetes 
mellitus (DM).5,6 Historically, traumatic injuries were the leading cause of LEA in 
LMICs;7,8,9 however, as non-communicable diseases (NCDs) in LMICs are increasing 
and infectious diseases are still prevalent, these nations are facing a double burden 
of medical indications for LEA.10 In a study from Cape Town, South Africa, the most 
common cause of non-traumatic LEA was DM.11  
 
Long-term mortality after LEA is high in HICs. Studies from HICs report 30-day 
mortality to be 9-30%12,13 and a meta-analysis demonstrated a 48% 1-year mortality 
(1YM) among patients with PVD and DM.14 The most common causes of death after 
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amputation are cardiac complications.15 Risk factors for death after LEA include 
surgical factors such as higher level of amputation, the need for staged procedures, 
as well as associated co-morbidities such as age >80 years, preoperative sepsis, DM, 
arteriosclerosis, coronary artery disease, cerebral vascular disease, and end- stage 
renal disease.14,16,17,18  
 
In LMICs, there is a paucity of data describing long-term mortality after LEA and 
associated risk factors. In a systematic review from Nigeria, POMR was reported at 
11% although 30-day and 1YM were not captured.9 A systematic review of all LEA 
for DM in Africa reported a 14% POMR.19 Long-term mortality after LEA is one factor 
considered when determining best buys for essential surgical packages in resource-
limited settings.  The primary aim of this study was to report 30-day and 1YM after 
LEA from an upper middle- income country, South Africa. The secondary objectives 
were to report risk factors for 1YM. 
 
Methods 
 
Study design and period 
This was a retrospective cohort study of patients undergoing LEA at New Somerset 
Hospital (NSH) from October 1, 2015, to October 31, 2016. 
 
Study population 
NSH is a second-level government hospital in Cape Town, South Africa which serves 
a catchment population of approximately 500,000 persons. Major extremity trauma 
cases are referred to a third- level hospital, Groote Schuur Hospital, approximately 
10km away. All patients undergoing LEA at NSH during the study period were 
included. Patients undergoing upper extremity amputations, or non-amputation 
procedures concomitant to LEA, were excluded. Patients under 18 years of age were 
also excluded. 
 
Ethics approval 
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Ethics approval was given by the University of Cape Town Human Ethics Committee. 
 
 
Data collection 
A hospital operative electronic database used for routine monitoring and evaluation 
was queried to identify eligible patients and operative characteristics. A medical 
record review was undertaken to identify co-morbidities and mortality. The following 
patient demographics and co-morbidities were captured: age, gender, PVD, DM, 
hypertension (HTN), smoking status, and previous LEA on a contralateral limb. 
Surgical variables included: type of LEA, trauma, and multiple LEA (more than one 
amputation on the same limb during the study period). Type of LEA included toe, 
trans-metatarsal, supra-malleolar (Guillotine), below knee (BKA), and above knee 
amputations (AKA). The level of amputation depended on the level of vascular 
disease or injury. Clinical criteria were used for many patients rather than vascular 
imaging due to limited resources.  Revascularization and angioplasty were available 
at the third-level hospital and prospective candidates were referred there prior to 
decision for amputation.  In this resource-limited setting, people with multiple 
comorbidities disease distal to the popliteal fossa were usually not considered 
candidates for revascularization and angioplasty.  Outcome status was defined as 
alive, dead, or lost to follow-up (LTFU). Outcome status was obtained from three 
sources. First, patients or their next of kin were traced telephonically after giving 
verbal consent during two tracing episodes: March-April 2017 and August 2018. For 
each tracing episode, three attempts were made to contact each patient/next of kin. 
Second, a search for deaths at Western Cape government hospitals using a 
centralized computerized administration system (CLINICOM) was undertaken.20 [20] 
Finally, deaths of patients with South African identification numbers (through March 
16, 2018) were identified through the National Population Register. Patients not 
traced and/or were not confirmed dead were considered LTFU. 30- day mortality was 
defined as death within 30 days of LEA. If more than one LEA was performed during 
the study period, mortality was calculated from the last procedure. 1YM was defined 
as death within 365 days of the last LEA. 
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Statistical analysis 
Descriptive statistics were used to describe patients’ and operative characteristics. 
Univariate and multivariate analysis were performed to find associations with 1YM. 
Age and gender were included a priori and all other variables with a p value<0.2 on 
univariate analysis were included in the multivariate analysis. Previous and multiple 
LEA were combined into one variable. The data were de-identified before analysis 
and all databases were security encoded. 
 
Results 
 
There were 152 patients; 90 (59%) males and the median age (interquartile range, 
IQR) was 60 (54-67) years. Co-morbidities were available for 137 (90%) of the 
cohort. Of these, 108 (79%) had PVD and 91 (66%) had DM. Majority of patients 
had gangrene (89%), with half having wet gangrene and the other half dry 
gangrene. Fifty-three (35%) had a prior LEA on the same or the contralateral limb or 
a second LEA during the study period. Only 4 (3%) LEA were performed for 
traumatic injury. Patient demographics are shown in Table 1. 
 
 
Operative Characteristics 
 
There were 183 LEA in 152 patients. The most common LEA was AKA (n=104, 57%), 
followed by BKA (n=36, 20%). See Table 2. 
 
Outcomes 
 
At 30 days, 102 (67%) of 152 were traced. Of these 12 (12%) were dead. At one 
year, 86 (57%) were traced. Of these, 37 (43%) were dead. At the end of the study, 
there was a median follow-up time of 522 (interquartile range: 190-801) days. A 
Kaplan Meier survival curve is shown in Figure 1. 
 
Associations with One Year Mortality 
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On univariate analysis, age ≥ 75 years of age, male gender, and AKA were 
associated with 1YM and included in the multivariate analysis (Table 3).  On 
multivariate analysis, age≥ 75 years (OR 7.81, p=0.017) were associated with 1YM. 
See Table 3. 
 
Discussion 
At this second- level government hospital in South Africa, 40% of patients 
undergoing LEA were dead after one year. While this proportion is high, it is lower or 
consistent with the rates in some HICs.14,21 Additionally, age was a risk factor for 
death after LEA.  
 
Only 3% LEA were performed for traumatic injury. While, trauma is a major 
contributor to LEA in LMICs, at this second-level hospital, trauma patients were 
usually referred to a third level hospital for specialized care. 
 
In our study, most LEA patients had a prior history of HTN, PVD, DM, or smoking 
without preceding trauma. Furthermore, majority of patients had gangrene with half 
presenting with wet gangrene. Therefore, long-term mortality after LEA is not 
surprising given these major co-morbidities. While our study did not report cause- 
specific mortality, other studies have shown that cardiac complications from 
microcirculation and vascular perfusion damage are the most common causes of 
death after LEA.15 
 
South Africa is rolling out a National Health Insurance plan and will likely include an 
essential basket of surgical procedures.22 Given the resource limitations in LMICs, 
each surgical procedure needs to be evaluated to determine if it is a “best buy”. 
Several factors are needed to set surgical priorities including quality-adjusted life 
years gained, indirect and direct costs to the health system and patient, and post-
operative outcomes.3 Ease of suffering and respect and dignity are also issues of 
concern when assessing the impact of an intervention.23 This study is significant in 
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that it demonstrates long-term mortality after LEA can be high and therefore impacts 
its value as a “best buy” under universal health coverage for South Africa. 
 
This was a retrospective manual review of secondary data. The data is subject to 
memory or registry bias. There are additional factors and comorbidities, and the 
causes of mortality that may be important in the risk factor analysis but were 
unavailable at the time of data collection. Furthermore, a longer time period would 
have likely resulted in a larger sample size and increased statistical power. One 
limitation of our study was that one-third of our patients were LTFU at 30 days and 
more than 40% by one year. It is likely that a large proportion of LTFU patients were 
actually alive since they were not recorded as dead in CLINCOM nor the National 
Population Registry. Therefore, 30- day mortality may have been as low as 8% and 
1YM 24% if all LFTU were considered alive. In addition, cost data, which are 
important in determining best buys, were not evaluated in this study.  
 
Conclusion 
 
At New Somerset Hospital in Cape Town, South Africa, up to 43% of patients were 
dead one year after LEA.  Long-term mortality needs to be considered when deciding 
which surgical procedures should be considered in universal health coverage in 
national surgical planning.  
 
What is already known on this topic 
• Lower extremity amputation (LEA) is a common surgical procedure; 
• Long-term mortality after LEA is high in high income countries; 
• There is a paucity of data describing long-term mortality after LEA and 
associated risk factors in lower to middle-income countries. 
 
What this study adds 
• One-year mortality after LEA in a government hospital in South Africa, an 
upper-middle income country, was 43%; 
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• The results from this study provide useful data to define the appropriate 
basket of surgical procedures for universal health coverage in resource-limited 
settings.  
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5. Tables and Figures 
 
Table 1: Patient characteristics of lower extremity amputation at a second-level 
government hospital in South Africa 
 
 n (%) 
Total cohort 152 
 
Mean age (interquartile range) 
 
60 (54-67) 
Males 90 (59) 
Co-morbidities *  
Peripheral vascular disease 108 (79) 
Hypertension 95 (69) 
Diabetes 91 (66) 
Smoking 70 (51) 
Operative indications  
Gangrene  135 (89) 
Wet  67 (50) 
Dry  68 (50) 
Trauma 4 (3) 
Multiple lower extremity amputation ** 53 (35) 
* n=137 
** more than one LEA on the same or contralateral limb  
 
 
Table 2: Types of lower extremity amputation performed at a second-level 
government hospital in South Africa 
 
Procedures 
 
N (%) 
Above knee amputation 104 (57) 
Below knee amputation 36 (20) 
Toe amputation 19 (10) 
Supra-malleolar amputation 18 (10) 
Trans-metatarsel amputation 6 (3) 
 
Total 
 
183 (100) 
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Table 3: Risk factors for one-year morality after lower extremity amputation  
 Univariate Analysis Multivariate Analysis 
  OR 
Confidence 
Interval 
P 
Value OR 
Confidence 
Interval 
P 
Value 
Demographics       
Age ≥75 years 6.43 1.29- 32.05 0.023 7.81 1.45- 42.20 0.017 
Male gender  1.89 0.76- 4.74 0.172 2.15 0.80- 5.77 0.129 
Co-morbidities       
Peripheral  
vascular disease 1.32 0.39- 4.48 0.659      
   
Hypertension 1.33 0.49- 3.62 0.573    
Diabetes mellitus 0.97 0.38- 2.51 0.954    
Smoking 1.23 0.49- 3.09 0.654         
Operative 
Indications    
   
Wet gangrene 1.30 0.51-3.28 0.582    
Trauma 2.34 0.20- 26.95 0.494         
Operation       
Above knee  
amputation 2.14 0.75- 6.08 0.152      
2.35 0.77- 7.20 0.134 
Below knee  
amputation 0.44 0.12- 1.59 0.212      
   
Supra-malleolar  
amputation 1.00   
   
Trans-metatarsal  
amputation 1.14 0.15- 8.54 0.896      
   
Toe Amputation 1.00      
Multiple lower 
extremity 
amputation* 0.54 0.21- 1.41 0.211      
   
OR, odds ratio 
*more than one LEA on the same or contralateral limb  
Risk factors with a p value <0.2 on univariate analysis were included in the 
multivariate analysis 
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Figure 1: Deaths over time after lower extremity amputation at a second-level 
government hospital in South Africa 
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Prior to submit your first article, you should apply for a user name and password. PAMJ offers a user 
friendly process for online submission.  
Short reports will include case report, commentary, conference proceedings, editorials, viewpoints, and 
letter to the editors. Short Communications should be no longer than 1500 words. They must have an 
abstract and references, but the main body of the text does not have to follow the original research’s 
format. We give privilege to invited reviews and encourage prospective authors of systematic reviews to 
discuss the project with the editorial office before development.  
After initial screening, which takes only a few days, manuscripts are sent to two-three referees. If 
appropriate, a statistical reviewer is involved. On average, we will report back to authors within 4-6 weeks 
with a first decision.  
Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by 
anyone on their behalf. The submitting author takes responsibility for the article during submission and 
peer review.  
Languages of publication are English and French. Each author should provide an abstract of his article in 
the other language prior to submission. Poor English of French do not prevent acceptance provided the 
paper's content is of high scientific quality. All accepted manuscripts are copy-edited.  
To facilitate rapid publication and to minimize administrative costs, PAMJ accepts only online submission. 
The submission process is compatible with version 3.0 or later of Internet Explorer, Opera, and Netscape 
Navigator.  
Files can be submitted as a batch. The submission process allows the authors to interrupt it at any time, and 
continue where they left off at their return on the site.  
During submission you will be asked to provide a cover letter. Use this to explain why your manuscript 
should be published in the journal and to elaborate on any issues relating to our editorial policies detailed 
in the instructions for authors.  
Assistance with the process of manuscript preparation and submission is available from the customer 
support team (submission@panafrican-med-journal.com). We also provide a collection of links to useful 
tools and resources for scientific authors, on our resources for authors’ page.  
2. Submission of a paper Online submission  
Authors may submit article to Pan African Medical Journal online. Simple onscreen instructions are 
provided.  
Submission by email  
Authors may submit article by email if the have limited or unstable Internet connection. Articles and 
associated material should be sent to any of the following email address:  
• submission@panafrican-med-journal.com Conflict of interest  
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Will be mentioned in the manuscript as "Authors declared they have no conflict of interest". The editorial 
office will acknowledge receipt of all manuscripts by email 
3. Organization of a full-length paper 
Download the journal manuscript template.  
Maximum length: 4000 words in main text (i.e., excluding abstract, references, legends, tables and 
figures), 6 tables/figures, and a structured abstract of 250 words plus up to 50 references.  
Title page – This page should states: a) The title of the paper (include the study design if appropriate; for 
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control study), b) Authors names (full name – no qualification), c) institution(s) of origin, d) 
Corresponding author plus his/her address, telephone and fax number, e-mail address, e) Word count (for 
both abstract and the main text)  
Abstract - The abstract of the manuscript should not exceed 250 words and must be structured into 
separate sections: Background: the context and purpose of the study; Method: how the study was 
performed and statistical tests used; Results: the main findings; Conclusion: brief summary and potential 
implications. Please minimize the use of abbreviations and do not cite references in the abstract.  
Keywords. Up to ten keywords (suitable for Index Medicus listing) should be provided at the end of the 
Abstract. Abbreviations Please do not provide a list of abbreviations. Abbreviations should be spelled out 
the first time they appear in the text.  
Background The background section should be written from the standpoint of researchers without 
specialist knowledge in that area and must clearly state - and, if helpful, illustrate - the background to the 
research and its aims. Reports of clinical research should, where appropriate, include a summary of a 
search of the literature  
Method Sufficient information should be given to permit repetition of the experimental work. This should 
include the design of the study, the setting, the type of participants or materials involved, a clear 
description of all interventions and comparisons, and the type of analysis used, including a power 
calculation if appropriate.  
Results - The Results should be stated concisely without discussion and should not normally contain any 
references. The same data should not be presented in figures and tables. Do not repeat all the data that is 
set out in the tables or figures in the text; emphasize or summarize only important observations.  
Formatting tables  
• Any table should be able to old on a single page and should be included at the end of the manuscript. 
Download sample of correctly formatted tables (Microsoft Word 2002-2003, *.DOC): Table 1, Table 2.  
Formatting figures  
• Formats: PNG, JPEG only. MUST BE SUBMITTED AS SEPARATE FILES, not embedded in the 
main manuscript. Submit the best quality possible 
Files must be named with the three letter file extension appropriate to the file type (eg: .jpeg, .png). You 
will be asked to provide figure labels during the submission process. (The label is the small comment that 
usually goes with the figure. Example: Figure 1: Prevalence of diabetes in the study population aged 18 
years and above. Findings of the TRICARE Diabetes Study, Uganda, 2006.) 
If you use excel to generate your graph, avoid 3D, crowded axes, colored background, strong grid etc.. Use 
Tahoma font (size 10 maximum) for all items in your graphs (Title, legend, axes etc..). Expand your Excel 
graph to obtain a large image, copy and paste it in Paint (Microsoft Paint), crop any white border and save 
the image as PNG or JPEG. Loot at an acceptable formatted Excel graph here  
Discussion - The Discussion should deal with the interpretation of the results and not recapitulate them. 
We encourage authors to write their Discussion in a structured way, as follows:a) statement of principal 
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findings; b) strengths and weaknesses of the study; c) strengths and weaknesses in relation to other studies; 
d) discussion of important differences in results; e) meaning of the study; f) unanswered questions and 
future research.  
Conclusion - The conclusion should provide a brief summarize of the key findings, potential implications 
and the way forward.  
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permission to acknowledge from all those mentioned in the Acknowledgements. Please list the source(s) of 
funding for the study, for each author, and for the manuscript preparation in the acknowledgements 
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analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the 
manuscript for publication.  
Competing interest - Authors are responsible for recognizing and disclosing conflicts of interest that 
might bias their work. They should acknowledge in the manuscript all financial support for the work and 
other personal connections. Authors are required to complete a declaration of competing interests. All 
competing interests that are declared will be listed at the end of published articles. Where an author gives 
no competing interests, the listing will read 'The author(s) declare that they have no competing interests'. 
When completing your declaration, please consider the following questions:  
Financial competing interests  
• In the past five years have you received reimbursements, fees, funding, or salary from an 
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article-processing charge)? If so, please specify.  
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from the  
publication of this manuscript, either now or in the future? If so, please specify  
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• Do you have any other financial competing interests? If so, please specify. Non-financial 
competing interests  
• Are there any non-financial competing interests (political, personal, religious, ideological, 
academic, intellectual, commercial or any other) to declare in relation to this manuscript? If so, 
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• If you are unsure as to whether you, or one your co-authors, has a competing interest please 
discuss it with the editorial office.  
Authors' contributions - In order to give appropriate credit to each author of a paper, the 
individual contributions of authors to the manuscript should be specified in this section.  
References - References must be numbered consecutively, in square brackets, in the order in 
which they are cited in the text, followed by any in tables or legends. Reference citations should 
not appear in titles or headings. Each reference must have an individual reference number. Please 
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formatting their reference list, as this allows references to be automatically extracted. Examples of 
the PAMJ reference style are shown below. Please take care to follow the reference style 
precisely; references not in the correct style may be retyped, necessitating tedious proofreading.  
Manuscripts not formatted according to the Pamj style will be returned to the authors. For all 
research papers, make sure your manuscript includes the following sections: Background, 
Method, Results, Discussion, Conclusion, List of tables and Figures, Conflicts of interests, 
Authors’ contribution, Acknowledgment (if any) and References. Pay special attention to 
citations in the manuscript. Pamj citation format is [1], [1-2], [X1,X2....] and NOT X1, X3, or 
anything else. . Manuscript not following these basic formatting rules will be returned illico 
presto. A basic sample for reference is provided below (We follow PubMed format for citing 
articles):  
1. Kirikou Thomas, Doe John, Shaba Kevin, Kashawa Tuma. A sample of the pamj reference style 
as shown on the journal website. J Hist Fant. 2006; 76(11):204-212  
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Author1 LastName FirstName, Author2 LastName FirstName, Author3 LastName FirstName, 
AuthorX LastName FirstName. Artitle title. Journal Year; Volume(Issue): StartPage-EndPage. 
Note that author names, article title, journal name can not contain dots.  
4. Short communication  
A maximum of 1500 words in the main text (i.e. excluding abstract, references and legends) plus 
up to ten references and normally no more than two illustrations (tables or figures or one of each). 
Otherwise in the same format as full- length original papers (see above).  
5. Review  
A maximum of 5000 words in the main text (i.e. excluding abstract, references and legends) plus 
up to 100 references. Reviews are usually solicited, although unsolicited Reviews may be 
considered for publication. Prospective writers of Reviews should first consult the Editors  
6. Letters to the Editors  
Comment briefly on findings of Journal articles or other noteworthy public health advances (up to 800 
words in main text, no abstract, limited to 10 references). Please note that word counts refer exclusively to 
the main text and do not include abstract, references, or acknowledgments.  
7. Commentaries  
Up to 2500 words in main text, 2 tables/figures, and an unstructured abstract of 120 words.  
8. Essays  
Analytical essays provide a forum for critical analyses of public health issues from disciplines other than 
the biomedical sciences, including (but not limited to) the social sciences, human rights, and ethics (up to 
3500 words in main text, 4 tables/figures, and an unstructured abstract of 120 words). Essays in the Health 
Policy and Ethics Forum present critical views on public health policy and ethics controversies 
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9. Debate  
This is designed to present a forum for critical debate about timely public health topics (up to 1000 words, 
10 references).  
10. Briefs  
Report Preliminary or novel findings may be reported as (up to 800 words in main text, 2 tables/figures, 
and an abstract of up to 80 words).  
11. Supplements and workshop reports  
We welcome conferences proceedings. Prospective conference organizers should contact the editorial 
office with the project for specific instructions.  
12. Revised manuscripts  
If you are asked to revise your manuscript you will be expected to provide a covering letter that responds 
in detail to each point raised by reviewers or editors, and to highlight new material in the text using a 
different color (do not use the 'track changes' mode of Word). If a manuscript returned to the authors for 
revision is not returned to the Editorial Office within the stipulated time-period (usually 4 weeks), it will be 
treated as a new manuscript.  
13. Proofs  
An email is sent to the corresponding author. Typographical errors only should be corrected. The corrected 
proof should be returned within 48 h. Failure to comply with this deadline will delay publication. Any 
changes to the text or figures are liable to be charged to the author.  
14. Permissions  
Verbatim material or illustrations taken from other published sources must be accompanied by a written 
statement from the author, and from the publisher if holding the copyright, giving permission to PAMJ for 
reproduction.  
15. Copyright  
The author(s) keep(s) the copyright to his/their article if and when the article is accepted for publication. 
The copyright covers the exclusive and unlimited rights to reproduce and distribute the article in any form 
of reproduction (printing, electronic media or any other form); it also covers translation rights for all 
languages and countries. For more information about the copyright, see our copyright agreement.  
Publication and peer review processes  
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PAMJ uses online peer review to speed up the publication process. Submitted manuscripts will be sent to 
peer reviewers, unless they are either out of scope or below threshold for the journal, or the presentation or 
written English/French is of an unacceptably low standard.  
Competing interests from are seek from authors and reviewers. Reviewers declare any competing interests 
and have to agree to open peer review. This implies that authors and reviewers agreed that if the 
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ethics committee. Research carried out on humans must be in compliance with the Helsinki Declaration, 
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